HeartBeam (NASDAQ: BEAT) reported first-quarter 2026 operational and financial results, highlighting the launch of its initial commercial partnerships in key U.S. markets, progress in its heart attack detection and ambulatory ECG patch initiatives, and an April public offering that raised $11.5 million in gross proceeds. The company reported a first-quarter net loss of $4.7 million, improved from $5.5 million in the prior-year period, with research and development expenses declining year over year as HeartBeam continued advancing commercialization of its FDA-cleared cardiac monitoring platform and related growth initiatives.
The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025.
The successful launch of commercial partnerships marks a significant milestone for HeartBeam as it transitions from development to revenue generation. The company's ambulatory ECG patch initiative aims to provide continuous monitoring for patients, addressing the growing need for remote cardiac care. The $11.5 million raised in April strengthens HeartBeam's balance sheet to support these efforts. For full details, the press release is available at https://ibn.fm/guMCF.
HeartBeam holds over 20 issued patents related to its technology. The cleared indications for use for the HeartBeam System with 12-Lead ECG synthesis software are available at https://www.heartbeam.com/indications. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT.
The company's forward-looking statements involve risks and uncertainties, including those set forth under "Risk Factors" in its SEC filings. HeartBeam undertakes no duty to update this information unless required by law.
